Sapan Muzaffer, Ozben Beste, Yakupoglu Gulsen, Suleymanlar Gultekin, Ozben Tomris
Department of Nephrology, Akdeniz University, Medical Faculty, Antalya, Turkey.
J Investig Med. 2009 Feb;57(2):456-9. doi: 10.2310/JIM.0b013e318197da68.
Posttransplant hyperlipidemia increases cardiovascular morbidity and mortality rate in renal transplant recipients. It also leads to graft loss due to atherosclerosis and glomerular damage. It is essential to control hyperlipidemia in renal transplant recipients to prevent these events.
In our study, we determined lipid profiles in 59 renal transplant recipients. Twenty of the recipients had hyperlipidemia; 9 had type IV, and 11 had type II hyperlipoproteinemia. Randomly selected 14 of 20 hyperlipidemic patients consisted of the diet group and were treated with American phase 3 diet for 1 month. Randomly selected 6 of the 20 hyperlipidemic patients received their regular diet as the control group. Five diet-resistant patients in the American phase 3 diet group were given diet plus placebo for another 1 month and then they were given diet plus Gemfibrozil (600 mg twice a day) for 2 months.
Lipid profile was normalized in 9 of the 14 patients on American phase 3 diet. The lipid profile of 5 patients in the American phase 3 diet group did not change significantly after 1-month diet. These 5 diet-resistant patients were given diet plus placebo for another 1 month, and their lipid levels again did not change significantly. Afterward, they were treated with Gemfibrozil (600 mg twice a day) plus American phase 3 diet for 2 months. At the end of this therapy period, their cholesterol level and triglyceride level decreased significantly. No change was observed in low-density lipoprotein cholesterol and high-density lipoprotein cholesterol levels.
We conclude that American phase 3 diet and/or Gemfibrozil are effective in controlling posttransplant hyperlipidemia in renal transplant recipients.
移植后高脂血症会增加肾移植受者的心血管发病率和死亡率。它还会因动脉粥样硬化和肾小球损伤导致移植肾失功。控制肾移植受者的高脂血症以预防这些事件至关重要。
在我们的研究中，我们测定了59名肾移植受者的血脂谱。其中20名受者患有高脂血症；9名患有IV型，11名患有II型高脂蛋白血症。从20名高脂血症患者中随机选取14名组成饮食组，接受美国3期饮食治疗1个月。从20名高脂血症患者中随机选取6名接受常规饮食作为对照组。美国3期饮食组中有5名对饮食治疗无效的患者再接受1个月的饮食加安慰剂治疗，然后接受饮食加吉非贝齐（600毫克，每日两次）治疗2个月。
接受美国3期饮食治疗的14名患者中有9名血脂谱恢复正常。美国3期饮食组中有5名患者在1个月的饮食治疗后血脂谱无明显变化。这5名对饮食治疗无效的患者再接受1个月的饮食加安慰剂治疗，其血脂水平再次无明显变化。之后，他们接受吉非贝齐（600毫克，每日两次）加美国3期饮食治疗2个月。在该治疗期结束时，他们的胆固醇水平和甘油三酯水平显著下降。低密度脂蛋白胆固醇和高密度脂蛋白胆固醇水平未观察到变化。
我们得出结论，美国3期饮食和/或吉非贝齐在控制肾移植受者移植后高脂血症方面有效。
